Clin Liver Dis. 2026 May;30(2):301-322. doi: 10.1016/j.cld.2025.12.003. Epub 2026 Feb 27.
ABSTRACT
Metabolic dysfunction-associated steatotic liver disease (MASLD), recently redefined to emphasize its metabolic underpinnings, is emerging as a systemic disorder that extends well beyond the liver. Accumulating evidence demonstrates a strong bidirectional association between MASLD, cardiovascular disease (CVD), and chronic kidney disease (CKD). Shared risk factors-including obesity, insulin resistance, hypertension, and dyslipidemia-partly explain this overlap, but common pathogenic mechanisms are increasingly recognized. Hepatic steatosis and inflammation contribute to systemic insulin resistance, atherogenic dyslipidemia, endothelial dysfunction, and a pro-inflammatory, prothrombotic milieu, thereby accelerating cardiovascular injury.
PMID:42142895 | DOI:10.1016/j.cld.2025.12.003